Allogene Therapeutics(ALLO) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update • Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) ◦ Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024 ◦ Patient Screening for Minimal Residual Disease (MRD) and Enrollment Proceeding as Planned with Ten Community and Academic Sites Opened to Date Across the US ◦ Enrollment Completion Expected in 1H 2026 and Potential BLA Submission in 2027 • ALLO-329 in Autoimmune D ...